National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

Understanding Cancer Series: Angiogenesis
< Back to Main
In English En español
    Posted: 01/28/2005    Reviewed: 09/01/2006
Page Options
Print This Page  Print This Page
Print This Document  Print This Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
PDF Version  View/Print PDF
PowerPoint Version  View/Print PowerPoint
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

President's Cancer Panel Annual Report: 2006-2007

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Slide 21 : Drugs That Inhibit Angiogenesis Directly previousnext

One class of angiogenesis inhibitors being tested in cancer patients are molecules that directly inhibit the growth of endothelial cells. Included in this category is endostatin, the naturally occurring protein known to inhibit tumor growth in animals. Another drug, combretastatin A4, causes growing endothelial cells to commit suicide (apoptosis). Other drugs, which interact with a molecule called integrin, also can promote the destruction of proliferating endothelial cells.

Drugs That Inhibit Angiogenesis Directly

< Previous  |  Index  |  Next Slide >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov